id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-327095-y2zsm8sc	Boretti, Alberto	Favipiravir use for SARS CoV-2 infection	2020-10-27		.txt	text/plain	2310	158	55	For the specific use against SARS CoV-2, [22] evaluated the in vitro efficacy of different drugs, from Remdesivir to Chloroquine, also including Favipiravir. Li and De Clercq [23] include Favipiravir together with Remdesivir, Galidesivir, and Ribavirin in between the existing antiviral agents' RNA-dependent RNA polymerase inhibitors to repurpose to treat SARS CoV-2 infection. [24] also include Favipiravir, together with Chloroquine, Arbidol, and Remdesivir, all under clinical studies in China to test their efficacy and safety for SARS CoV-2 infection. Up to date, there is not enough information from specific trials to infer any conclusion on the use of Favipiravir for SARS CoV-2 infection. SARS-CoV-2: recent reports on antiviral therapies based on lopinavir/ritonavir, darunavir/umifenovir, hydroxychloroquine, remdesivir, favipiravir and other drugs for the treatment of the new coronavirus Dose rationale for favipiravir use in patients infected with SARS-CoV-2	./cache/cord-327095-y2zsm8sc.txt	./txt/cord-327095-y2zsm8sc.txt